Everolimus

About

Therapy type: Targeted therapy

Therapy strategy: PI3K/AKT/mTOR inhibition

Mappings

NCI Thesaurus: Everolimus (ncit:C48387)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Everolimus, Exemestane
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
Sensitivity (+) TSC1 oncogenic variants Renal Angiomyolipoma Everolimus
Sensitivity (+) TSC2 oncogenic variants Renal Angiomyolipoma Everolimus
Sensitivity (+) TSC1 oncogenic variants Anaplastic Thyroid Cancer Everolimus
Sensitivity (+) TSC2 oncogenic variants Anaplastic Thyroid Cancer Everolimus
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Everolimus, Exemestane
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Everolimus, Exemestane
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane